Celgene to Acquire Receptos, Advancing the Potential of Ozanimod for the Treatment of Ulcerative Colitis

Celgene to Acquire Receptos, Advancing the Potential of Ozanimod for the Treatment of Ulcerative Colitis
This week Celgene Corporation, a global biopharmaceutical company engaged primarily in the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation, announced that it has signed an agreement in which it will acquire Receptos, Inc. (NASDAQ: RCPT) a biopharmaceutical company that specializes in the  development of

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *